What is Gilead Sciences's livdelzi — total revenues?

Gilead Sciences (GILD) reported livdelzi — total revenues of $133M in Q1 2026.

What does livdelzi — total revenues mean?

Total revenue generated from the sales of the liver disease medication Livdelzi.

How do you interpret livdelzi — total revenues?

An increase indicates successful market penetration, strong physician adoption, or effective commercial execution for this specific therapy, while a decrease may signal increased competition, loss of market share, or changes in patient access.

How does livdelzi — total revenues compare across companies?

Comparable to revenue metrics for specific specialty pharmaceutical assets or niche therapeutic products within the portfolios of other large-cap biopharmaceutical companies.

Gilead Sciences GILD Livdelzi — Total revenues

Other product segments

Biktarvy

$3.36B+6.7%

Descovy

$807M+37.7%

Trodelvy

$402M+37.2%

Yescarta

$332M-14.0%

Sofosbuvir/Velpatasvir

$283M-18.2%

Genvoya

$264M-27.5%

Vemlidy

$237M-6.0%

Odefsey

$221M-21.4%

Yeztugo

$166M—

Veklury

$144M-52.3%

AmBisome

$138M-0.7%

Symtuza - Revenue share

$138M+21.1%

Other Liver Disease

$114M-5.8%

Tecartus

$75M-3.8%

Other HIV

$73M-19.8%

Other

$58M-17.1%

Royalty, contract and other revenues

$14M-74.1%

Similar metrics at other companies

JAZZDefitelio — Revenue

$40.5M+33.9%

JAZZDefitelio/defibrotide — Revenue from Contract with Customer, Excluding Assessed Tax

$47.4M+16.5%

IONSTegsedi And Waylivra — Revenue

$13.53M+65.2%

IONSWaylivra — Revenue

$6M—

PODDDrug Delivery — Total Revenue

$3.3M-77.9%

BMRNNAGLAZYME — Total revenues

$130.07M+13.8%

Other financials

Income statement

See full

Revenue$7.0B+4.4%

Gross profit$5.5B+7.6%

Operating income$2.6B+15.6%

Net income$2.0B+53.7%

EPS (diluted)$1.61+54.8%

Balance sheet

See full

Cash & equivalents$7.6B-3.8%

Total debt$22.2B-11.1%

Total equity$23.5B+22.7%

Total assets$56.3B-0.3%

Cash flow

See full

Operating cash flow$2.5B+44.8%

CapEx$117.0M+12.5%

Free cash flow$2.4B+46.8%

Valuation

See full

Market cap$153.66B+23.8%

Enterprise value$168.2B+19.7%

P/E16.7×-4.1×

P/S5.2×+0.8×

Profitability

See full

Gross margin79.4%+1.1pp

Operating margin34.9%+6.3pp

Net margin31%+10.2pp

Returns & leverage

See full

Return on equity43.2%+10.7pp

Debt / equity0.9×-0.4×

Current ratio2×+0.6×

Where this comes from

Reported directly by Gilead Sciences in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The official record: Gilead Sciences’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Gilead Sciences's livdelzi — total revenues.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Gilead Sciences's livdelzi — total revenues?: Gilead Sciences (GILD) reported livdelzi — total revenues of $133M in Q1 2026.
What does livdelzi — total revenues mean?: Total revenue generated from the sales of the liver disease medication Livdelzi.
How do you interpret livdelzi — total revenues?: An increase indicates successful market penetration, strong physician adoption, or effective commercial execution for this specific therapy, while a decrease may signal increased competition, loss of market share, or changes in patient access.
How does livdelzi — total revenues compare across companies?: Comparable to revenue metrics for specific specialty pharmaceutical assets or niche therapeutic products within the portfolios of other large-cap biopharmaceutical companies.